More on CRVS
Data
Upcoming Events
News
|
|||||
|---|---|---|---|---|---|
| Prev. Close | $3.62 |
|
|||
| Open | $3.57 | ||||
| 52 Wk High | $17.77 | ||||
| 52 Wk Low | $9.63 | ||||
| Day High | $3.67 | ||||
| Day Low | $3.51 | ||||
| P/E | N/A | ||||
| EPS | $0.00 | ||||
| Volume | 480,030 | ||||
- Form DEFA14A Corvus Pharmaceuticals,
- Form DEF 14A Corvus Pharmaceuticals, For: Jun 12
- Corvus Pharmaceuticals to Present New Interim Data from Placebo-Controlled Phase 1 Clinical Trial of Soquelitinib for Atopic Dermatitis on May 8, 2025
- Form 4 Corvus Pharmaceuticals, For: Apr 08 Filed by: van den Broek Richard
- Form 3 Corvus Pharmaceuticals, For: Apr 08 Filed by: van den Broek Richard
- Form 8-K Corvus Pharmaceuticals, For: Apr 08
- Corvus Pharma (CRVS) Appoints Richard A. van den Broek to Board of Directors
- Corvus Pharmaceuticals Appoints Richard A. van den Broek to Board of Directors
- Corvus Pharmaceuticals (CRVS) PT Raised to $15 at Oppenheimer
- H.C. Wainwright Reiterates Buy Rating on Corvus Pharmaceuticals (CRVS)
Entities mentioned with CRVS
- FDA | View Related Stories »
- Earnings | View Related Stories »
- 13G | View Related Stories »
- ARK | View Related Stories »
- Credit Suisse | View Related Stories »
- Maynard Um | View Related Stories »
- Mark Zuckerberg | View Related Stories »
- OrbiMed Advisors | View Related Stories »
- Show More...
